P1.13. MDM2 Inhibition in Combination with MEK Inhibition in Pre-clinical Models of Lung Adenocarcinomas with MDM2 Amplification
Back to course
Pdf Summary
Asset Subtitle
Arielle Elkrief, Memorial Sloan Kettering Cancer Center, United States
Meta Tag
Speaker Arielle Elkrief, Memorial Sloan Kettering Cancer Center, United States
Topic Poster Listing
Keywords
MDM2
MEK inhibition
lung adenocarcinomas
MDM2 amplification
driver alterations
receptor tyrosine kinases
EGFR
RET
METex
ALK
Powered By